Table 1.
Characteristics of the study population.
| RA (n = 30) | SP (n = 30) | HC (n = 20) | |
|---|---|---|---|
| Age, years, median (IQR) | 49.5 (37–55) |
50 (38–56.3) | 47.5 (28–57) |
| Female | 93.3% | 6.7% | 55% |
| BMI, median (IQR) | 20.6 (19.5–22.1) | 21.2 (20.3–22.1) | 21.7 (20.3–22.4) |
| Anti CCP-positive | 100% | NA | NA |
| RF-positive | 90% | NA | NA |
| RF titer, kU/l, median (IQR) | 102 (24.4–415.3) | ||
| Anti CCP titer, kAU/l, median (IQR) |
478.5 (322.5–500) | ||
| Disease activity parameters | |||
| Disease duration, months, median (IQR) |
103 (57.3–135) | ||
| DAS28, median (IQR) | 4.2 (3.3–5.8) | ||
| CDAI, median (IQR) | 14 (10.5–15.8) | ||
| SDAI, median (IQR) | 16.5 (11.2–19) | ||
| Disease activity | |||
| High activity (H, %) | 26.7% | ||
| Middle activity (M, %) | 46.7% | ||
| Low activity (L, %) | 13.3% | ||
| Stable (S, %) | 13.3% | ||
| ESR, mm/h, median (IQR) | 30 (20.8–60.8) | ||
| CRP, mg/l, median (IQR) | 6.1 (2.1–13.8) | ||
| Medication use | |||
| Methotrexate (%) | 60.0% | ||
| Hydroxycholorquine (%) | 43.3% | ||
| Prednisone (%) | 56.7% | ||
| Leflunomide (%) | 30.0% | ||
| Cyclophosphamide (%) | 3.0% | ||
| Cyclosporine (%) | 3.0% | ||
| Tripterygium glycosides (%) | 6.7% | ||
| Total Glucosides of Paeony (%) | 6.7% | ||
BMI, body mass index; DAS, Disease Activity Score; CDAI, clinical disease activity index; SDAI, simplified disease activity index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; CCP, Anti-cyclic citrullinated peptide antibody; NA, Not available.